Last reviewed · How we verify

Quadrivalent virosomal influenza vaccine

Crucell Holland BV · Phase 1 active Biologic Quality 0/100

Quadrivalent virosomal influenza vaccine is a Biologic drug developed by Crucell Holland BV. It is currently in Phase 1 development. Also known as: Quadrivalent FluCell.

At a glance

Generic nameQuadrivalent virosomal influenza vaccine
Also known asQuadrivalent FluCell
SponsorCrucell Holland BV
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Quadrivalent virosomal influenza vaccine

What is Quadrivalent virosomal influenza vaccine?

Quadrivalent virosomal influenza vaccine is a Biologic drug developed by Crucell Holland BV.

Who makes Quadrivalent virosomal influenza vaccine?

Quadrivalent virosomal influenza vaccine is developed by Crucell Holland BV (see full Crucell Holland BV pipeline at /company/crucell-holland-bv).

Is Quadrivalent virosomal influenza vaccine also known as anything else?

Quadrivalent virosomal influenza vaccine is also known as Quadrivalent FluCell.

What development phase is Quadrivalent virosomal influenza vaccine in?

Quadrivalent virosomal influenza vaccine is in Phase 1.

Related